The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Braveheart Bio to present 52-week BHB-1893 data at AHA Sessions

Oct 30, 2026 11:30 (3h ago)

Verifying

Braveheart Bio announced two presentations at the AHA Scientific Sessions 2026.
BHB-1893's late-breaking presentation will cover results from a 52-week extension period.
Braveheart Bio is developing BHB-1893 for obstructive and non-obstructive HCM.